Boehringer Ingelheim Animal Health USA Inc v Zoetis Services LLC [2023] FCA 1119

Boehringer Ingelheim Animal Health USA Inc v Zoetis Services LLC [2023] FCA 1119

Claims 1 of the 535, 537, and 540 applications were found obvious in light of Okada 2000a (and related prior art) considered with the common general knowledge, as the skilled addressee would be motivated to make and test a supernatant vaccine and use available means to address antibody interference, though use of Protein A/G in the 'reverse' manner was inventive. The specifications did not enable or support claims that encompassed broad combinations with specified additional antigens, nor did they disclose the best method, as necessary information (such as antigen concentrations) was withheld, and kit claims were found unpatentable as mere collocations without functional interaction for...

Jurisdiction
Australia
Judgment Date
21 September 2023
Procedural Posture
Patent Opposition (appeal From Patent Office) / Judgment After Appeal and Cross Appeal (first Instance, Federal Court)
Outcome
Patent oppositions by Boehringer partly successful; most claims held invalid, only specified claims survive.
Legal Topics
['patents' 'inventive Step' 'support/sufficiency Requirement' 'best Method Requirement' 'construction of Claims' 'manner of Manufacture']
['intellectual Property'] ['patents' 'inventive Step' 'support/sufficiency Requirement' 'best Method Requirement' 'construction of Claims' 'manner of Manufacture']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Patent Opposition (appeal From Patent Office) / Judgment After Appeal and Cross Appeal (first Instance, Federal Court)

Legal Issues

  1. 1 ['Whether claims to M. hyo supernatant vaccine and its combinations involve an inventive step under ss 7(2) and (3) of the Patents Act 1990 (Cth) in light of prior art and common general knowledge' 'Whether the patent specifications provide enabling disclosure and support as required by s 40(2)(a) and s 40(3) of the Patents Act for the breadth of claims asserted' 'Whether the patent applications disclose the best method known to the applicant for performing the invention as at filing (s 40(2)(aa))' 'Whether certain kit claims comprise a patentable manner of manufacture or are merely collocations']

Ratio Decidendi

Claims 1 of the 535, 537, and 540 applications were found obvious in light of Okada 2000a (and related prior art) considered with the common general knowledge, as the skilled addressee would be motivated to make and test a supernatant vaccine and use available means to address antibody interference, though use of Protein A/G in the 'reverse' manner was inventive. The specifications did not enable or support claims that encompassed broad combinations with specified additional antigens, nor did they disclose the best method, as necessary information (such as antigen concentrations) was withheld, and kit claims were found unpatentable as mere collocations without functional interaction for...

Court Disposition

Patent oppositions by Boehringer partly successful; most claims held invalid, only specified claims survive.

Orders

  • ['If the parties agree on appropriate orders, file proposed orders by 5 October 2023; otherwise, each party to file and serve their proposed orders and three-page submissions by 5 October 2023.']